Kidney dialysis patients: new study tests blood thinner safety
NCT ID NCT04006093
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a single 5 mg dose of the blood thinner apixaban is processed in people with end-stage kidney disease who are on peritoneal dialysis, compared to people with normal kidney function. Researchers measured drug levels in the blood over time. The goal is to understand if dosing adjustments are needed for this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apixaban (a blood thinner)
What this could lead to
If successful, this could help doctors determine safe and effective dosing of apixaban for people on peritoneal dialysis.
What could go wrong
This is a small, early-phase study with only 24 participants, so results may not apply to everyone. It looks at drug levels, not clinical outcomes like bleeding or clotting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Caen
Caen, 14000, France